|
Post by mannmade on Aug 26, 2014 8:03:56 GMT -5
|
|
|
Post by babaoriley on Aug 26, 2014 8:19:16 GMT -5
Pretty safe point of view by the author. As far as the 6's, anything's possible, and no one knows.
|
|
|
Post by thekindaguyiyam on Aug 26, 2014 9:50:49 GMT -5
|
|
|
Post by kc on Aug 26, 2014 10:21:00 GMT -5
|
|
|
Post by thekindaguyiyam on Aug 26, 2014 18:26:01 GMT -5
You beat me to the original post KC. Had I seen it I wouldn't have duplicated. That link and this are just what we want to see. Thanks a lot for your contributions. i appreciate it. This is a Great link!
|
|
|
Post by seanismorris on Aug 27, 2014 11:11:59 GMT -5
Jefferies Group initiated coverage on shares of MannKind (NASDAQ:MNKD) in a research report released on Wednesday morning, TheFlyOnTheWall.com reports. The firm issued a buy rating and a $10.00 price objective on the stock. Shares of MannKind (NASDAQ:MNKD) opened at 7.34 on Wednesday. MannKind has a 52-week low of $3.80 and a 52-week high of $11.48. The stock has a 50-day moving average of $8.50 and a 200-day moving average of $7.60. The company’s market cap is $2.826 billion. MannKind also saw a large increase in short interest in August. As of August 15th, there was short interest totalling 77,343,842 shares, an increase of 6.6% from the July 31st total of 72,584,807 shares. Based on an average daily trading volume, of 17,109,430 shares, the days-to-cover ratio is presently 4.5 days. Currently, 31.0% of the company’s stock are short sold.
MannKind (NASDAQ:MNKD) last announced its earnings results on Monday, August 11th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.07. During the same quarter in the previous year, the company posted ($0.16) earnings per share. On average, analysts predict that MannKind will post $-0.38 earnings per share for the current fiscal year.
A number of other analysts have also recently weighed in on MNKD. Analysts at Zacks reiterated a neutral rating on shares of MannKind in a research note on Wednesday, August 13th. They now have a $7.75 price target on the stock. Separately, analysts at RBC Capital cut their price target on shares of MannKind from $16.00 to $13.00 in a research note on Tuesday, August 12th. They now have an outperform rating on the stock. Finally, analysts at ISI Group downgraded shares of MannKind from a buy rating to a hold rating in a research note on Tuesday, July 1st. They now have a $11.00 price target on the stock, up previously from $10.00. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. MannKind presently has a consensus rating of Hold and a consensus target price of $9.36. MannKind Corporation (NASDAQ:MNKD) is a development-stage biopharmaceutical company.
|
|
|
Post by seanismorris on Aug 27, 2014 11:15:49 GMT -5
Jefferies initiated coverage on MannKind (NASDAQ: MNKD) with a Buy rating and a price target of $10.00. Analyst Shaunak Deepak said he was taking a contrarian stance ahead of Afrezza launch. He sees peak Afrezza sales of $3.2 billion.
"MNKD is off 33% since the Afrezza approval, reflecting negative Street sentiment about the Sanofi partnership and upcoming launch. Key concerns include docs not adopting Afrezza as a first-line insulin, aggressive counter-detailing from Novo and Lilly to protect their stake in the $6b+ mealtime insulin market, and a bad track record with the only other approved inhaled insulin, Exubera," said Deepak.
"We believe Afrezza could address a major unmet need among patients poorly controlled with oral drugs that have not advanced to injectable agents. Surveys of insulin non-adherence suggest a not insubstantial portion of patients reject insulin due to reluctance to take shots. Accounting for other factors that influence patient avoidance of insulin, we believe Afrezza could be used as a first-line insulin for almost 8% of type 2 patients failing oral drugs, worth $1.6b in peak U.S. sales. We believe Sanofi would promote Afrezza as a first-line insulin to gain and retain patients for its $8b+ insulin franchise," he continued.
"While Afrezza has shown non-inferiority to Novolog as a mealtime add-on in both type 1 and type 2 diabetics, we believe the significantly better A1c reductions with Novolog will be a challenge for marketing Afrezza. Compounding this is the Street’s memory of Exubera as a flop associated with lung cancer. We believe some patients only on basal insulin will be attracted to Afrezza’s benefits in hypoglycemia and weight gain, while some current mealtime insulin users will be drawn to reductions in injection burden and the whistle-like delivery device, which is more discrete than Exubera’s. We expect modest 3% and 6% penetration among type 1 and type 2 patients already on insulin, contributing $200m and $650m in U.S. sales. We see Sanofi as strongly motivated to promote Afrezza in this setting as its mealtime insulin, Apidra, only has a 3% share," he added.
For an analyst ratings summary and ratings history on MannKind click here. For more ratings news on MannKind click here.
Shares of MannKind closed at $7.34 yesterday.http://www.streetinsider.com/Analyst+Comments/Jefferies+Sees+Peak+Afrezza+Sales+of+$3.2B,+Starts+MannKind+(MNKD)+at+Buy/9785895.html
|
|
|
Post by seanismorris on Aug 27, 2014 11:19:59 GMT -5
|
|
|
Post by kc on Aug 27, 2014 16:02:52 GMT -5
Great posting on the Barrons blog. blogs.barrons.com/stockstowatchtoday/2014/08/27/mannkind-why-jefferies-says-buy/#comment-2999559By Ben Levisohn Shares of MannKind (MNKD) have gained 1.8% to $7.47 at 3:49 p.m. today after Jefferies initiated the company at Buy. Jefferies analyst Shaunak Deepak explains why he’s bullish on MannKind’s shares: The Street Is Negatively Biased Against Afrezza Launch. MannKind is off 33% sincethe Afrezza approval, reflecting negative Street sentiment about the Sanofi partnership and upcoming launch. Key concerns include docs not adopting Afrezza as a first-line insulin, aggressive counter-detailing from Novo and Eli Lilly (LLY) to protect their stake in the $6b+ mealtime insulin market, and a bad track record with the only other approved inhaled insulin, Exubera. We Believe Afrezza Could Radically Grow Mealtime Insulin Use. We believe Afrezza could address a major unmet need among patients poorly controlled with oral drugs that have not advanced to injectable agents. Surveys of insulin non-adherence suggest a not insubstantial portion of patients reject insulin due to reluctance to take shots. Accounting for other factors that influence patient avoidance of insulin, we believe Afrezza could be used as a first-line insulin for almost 8% of type 2 patients failing oral drugs, worth $1.6b in peak U.S. sales. We believe Sanofi would promote Afrezza as a first-line insulin to gain and retain patients for its $8b+ insulin franchise. Deepak initiated MannKind with a price target of $10, 34% higher than its current price.
|
|
|
Post by EveningOfTheDay on Aug 29, 2014 22:47:54 GMT -5
Hi to all. I have been browsing this board for a while, got tired of all the drama on the YMB, and know many of you from it, but this is my first time posting, other than a short comment a few days ago.
I thought this was an interesting article on the a Sanofi Takeda collaboration signed recently.
Sanofi and Takeda Partner in Diabetes Patient Care in Japan
Although I do not currently reside in Japan, I have lived and worked in Tokyo for a number of years and I still visit the country on regular basis. I can confirm that the Japanese are notoriously needle phobic, and imo Afrezza will do INCREDIBLY well there. The only downside is that smoking is fairly prevalent in the country, although definitely less so among young people. As I also argued sometime ago on the other board, in other to be successful doing business in Japan one must have a strong domestic partner. The intricacies of Japanese bureaucracy are many and knowing the right people can considerably speed any process. Even though the article does not obviously mention Afrezza, the time of the announcement of this collaboration would seem to indicate that Sanofi understands very well the potential for it in the Japanese market and that they have been working for some time in setting the foundation for a trouble free launch.
Cheers and GLTAL
|
|
|
Post by 4Balance on Aug 30, 2014 1:14:21 GMT -5
Sanofi and Takeda Partner in Diabetes Patient Care in Japan
Although I do not currently reside in Japan, I have lived and worked in Tokyo for a number of years and I still visit the country on regular basis. I can confirm that the Japanese are notoriously needle phobic, and imo Afrezza will do INCREDIBLY well there. The only downside is that smoking is fairly prevalent in the country, although definitely less so among young people.
Do you find a significant difference between the genders? My personal experience has shown that far more male Koreans smoke vs. female Koreans...not sure if that can be proven statistically. But I wonder if the same pattern applies to Japanese males vs. females...??
|
|
|
Post by EveningOfTheDay on Aug 30, 2014 4:19:03 GMT -5
Do you find a significant difference between the genders? My personal experience has shown that far more male Koreans smoke vs. female Koreans...not sure if that can be proven statistically. But I wonder if the same pattern applies to Japanese males vs. females...?? You are absolutely right. Smoking is a lot more prevalent among males than females in Japan too. If I had to guess, I would say that approximately there must be, in the smoking population, a men to women ratio of 4 to 1. I can also tell you that in general in there seems to be a trend towards more healthy habits amongst both men and women, with a constant decline on the number of smokers over the last decade. As I said, what I have been able to observe is that young people tend to smoke far less. Yet the percentage of smokers is still considerably high with respect to the US, and I also wonder how many people are affected by second hand smoke. In any case, I am certain Afrezza has all the attributes become extremely successful in Japan. I would not be surprise if it took most of the pandrial insulin market in very few years. There is often discussion of how well Afrezza will do in the US, whether the treatment will be covered by insurance companies, etc. My point is that even if Afrezza proved a flop in the US, something i certainly do not anticipate to happen, or had a slow start, Mannkind and Sanofi still could do extremely well selling Afrezza in the ROW.
|
|
|
Post by 1 percenter on Aug 30, 2014 8:16:53 GMT -5
Re: selling Afrezza in Japan.
Just put it in a vending machine next to the one that sells alcohol and used panties. Those Japanese are quite perverted.
|
|
|
Post by jpg on Aug 30, 2014 20:52:21 GMT -5
Re: selling Afrezza in Japan. Just put it in a vending machine next to the one that sells alcohol and used panties. Those Japanese are quite perverted. Hi MM, Where did you see these specific vending machines? JPG
|
|
|
Post by 1 percenter on Aug 30, 2014 21:14:20 GMT -5
I personally have not been to japan but have read about it. There are youtube vids of people showing them. It is amazing they have such items to dispense and that there is demand for it.
|
|